Get the Stockscreener App
1.57
1.95%
0.03
Whitehawk Therapeutics Inc stock is traded at $1.57, with a volume of 50,279.
It is up +1.95% in the last 24 hours and up +0.00% over the past month.
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.
See More
Previous Close:
$1.54
Open:
$1.54
24h Volume:
50,279
Relative Volume:
1.34
Market Cap:
$80.00M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-3.09%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$1.53
$1.6062
1-Week Range:
$1.53
$1.77
52-Week Range:
$1.48
$2.09
Whitehawk Therapeutics Inc Stock (WHWK) Company Profile
Name
Whitehawk Therapeutics Inc
Sector
Industry
Phone
551-321-2234
Address
2 HEADQUARTERS PLAZA, MORRISTOWN
Compare WHWK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
WHWK
Whitehawk Therapeutics Inc
|
1.57 | 80.00M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Whitehawk Therapeutics Inc Stock (WHWK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-27-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-21-24 | Downgrade | Jefferies | Buy → Hold |
| Aug-21-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-15-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-11-22 | Initiated | Jefferies | Buy |
| Oct-01-21 | Initiated | Cowen | Outperform |
| Sep-14-21 | Initiated | Ladenburg Thalmann | Buy |
| Sep-08-21 | Initiated | Piper Sandler | Overweight |
View All
Whitehawk Therapeutics Inc Stock (WHWK) Latest News
Whitehawk Therapeutics - The Pharma Letter
Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations - MarketScreener
Aadi Bioscience to Participate at Upcoming Investor Conferences - MarketScreener
Aadi Bioscience to Participate in Upcoming Investor Events - MarketScreener
Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - MarketScreener
Aadi Bioscience Announces Poster Presentations on Nab-Sirolimus at the International Gynecologic Cancer Society (IGCS) 2023 Annual Global Meeting - MarketScreener
Aadi Bioscience to Present at the TD Cowen 44th Annual Healthcare Conference - MarketScreener
Aadi Bioscience, Inc. Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus in Patients with Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 Genes - MarketScreener
Earnings Flash (AADI) AADI BIOSCIENCE Posts Q4 Revenue $5.2M - MarketScreener
Whitehawk Therapeutics, Inc. SEC 10-K Report - TradingView
Kaken Pharmaceutical Co., Ltd. entered into a stock purchase agreement to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. for $100 million. - marketscreener.com
Whitehawk Therapeutics Closes Sale of Aadi Subsidiary to Kaken Pharmaceuticals - citybiz
Whitehawk Therapeutics sells subsidiary for $102.4 million By Investing.com - Investing.com South Africa
Whitehawk Therapeutics sells subsidiary for $102.4 million - Investing.com India
Whitehawk sells Aadi Subsidiary to Kaken for $100 million - Investing.com
Whitehawk sells Aadi Subsidiary to Kaken for $100 million By Investing.com - Investing.com UK
Whitehawk Therapeutics Completes Strategic Transformation With Successful Closing Of Sale Of Aadi Subsidiary To Kaken Pharmaceuticals - Marketscreener.com
Whitehawk Therapeutics Completes Strategic Transformation with Successful Closing of Sale of Aadi Subsidiary to Kaken Pharmaceuticals - The Victoria Advocate
Aadi Bioscience Announces $72.5 Million Private Placement Equity Financing - MarketScreener
Aadi Bioscience Announces Participation in Upcoming September Investor Conferences - MarketScreener
Aadi Bioscience Announces Leadership Transition - MarketScreener
Aadi Bioscience Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus at the 34th EORTC-NCI-AACR Symposium - MarketScreener
Aadi Bioscience, Inc. (NASDAQ:AADI) Q4 2024 Earnings Call Transcript - Insider Monkey
Aadi Bioscience’s Earnings Call: Strategic Shifts and Promising Pipeline - TipRanks
Aadi Bioscience, Inc. Appoints Baiteng Zhao to its Board of Directors - MarketScreener
Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update - Marketscreener.com
Aadi Bioscience Announces Financial Results for the Third Quarter 2024 and Provides Corporate Update - MarketScreener
Aadi Bioscience Announces Financial Results for the Second Quarter 2024 and Provides Corporate Update - Marketscreener.com
Aadi Bioscience, Inc. Announces CEO Changes - MarketScreener
Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO) - Marketscreener.com
Aadi Bioscience to Participate in the Jefferies Healthcare Conference - MarketScreener
Aadi Bioscience Appoints David Dornan, PhD, as Chief Scientific Officer - MarketScreener
Aadi Bioscience Announces Approval of All Proposals at Special Meeting of Stockholders - Marketscreener.com
Aadi Bioscience Inc (AADI) Q4 2024 Earnings Call Highlights: Strategic Transition and Financial ... By GuruFocus - Investing.com Canada
Whitehawk Therapeutics: Strategic Shift and Financial Outlook - TipRanks
Aadi rebrands as Whitehawk Therapeutics in new ADC focus - The Pharma Letter
Novartis cuts over 400 jobs ahead of Entresto patent loss - The Pharma Letter
Six new option listings and four option delistings on March 19th - TipRanks
Aadi Bioscience, Inc. will Change its Name to Whitehawk Therapeutics, Inc -March 19, 2025 at 12:00 am EDT - Marketscreener.com
Aadi Bioscience Inc changes name to Whitehawk Therapeutics -March 18, 2025 at 05:58 pm EDT - Marketscreener.com
Aadi Bioscience Inc changes name to Whitehawk Therapeutics - TradingView
Aadi Bioscience Relaunches as Whitehawk Therapeutics Marking Evolution into ADC Company - PR Newswire
Major Transformation: Aadi Becomes Whitehawk with $180M War Chest for ADC Cancer Programs - Stock Titan
Aadi Bioscience Announces Closing of $100 Million PIPE Financing - MarketScreener
WhiteHawk Capital Partners Provides Credit Facility to Nephron Pharmaceuticals - Business Wire
Finance Watch: Generation Bio, CytomX Right-Size Operations Ahead Of J.P. Morgan - insights.citeline.com
Asia Deal Watch: Kaken Obtains Aadi Subsidiary And Cancer Drug Fyarro - insights.citeline.com
PHX Minerals Explores Sale After Rejecting Acquisition Bids - Yahoo Finance
Aadi Bioscience downgraded to Neutral, shares fall (NASDAQ:AADI) - Seeking Alpha
Aadi Bioscience Provides PRECISION1 Trial and Corporate Updates - MarketScreener
Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update - MarketScreener
Whitehawk Therapeutics Inc Stock (WHWK) Financials Data
There is no financial data for Whitehawk Therapeutics Inc (WHWK). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):